Benchmarking Evaluation of Web System Using Fuzzy Sets

Jeong, Gu-Beom,Kim, Doo-Ywan,Her, Chol-Hoi Korean Institute of Intelligent Systems 2004 INTERNATIONAL JOURNAL of FUZZY LOGIC and INTELLIGE Vol.4 No.3

For Web System composed of a variety of hardware, software and network system, there is a wide difference in price, function and capacity. In addition, it is important to select the most suitable system when web system is constructed as the claim of high-quality web service from user has increased. Data of bench-marking is usually employed when the system is selected. Evaluation with the result of bench-marking, however, is not easy at web situation composed of a variety of systems. In this paper, first integrated bench-marking of hardware, software and network system metric were determined, and the plan to effectively compare and evaluate the result of bench-marking by using fuzzy set were offered.

Benchmarking Evaluation of Web System Using Fuzzy Sets

Gu-Beom Jeong,Doo-Ywan Kim,Chol-Hoi Her 한국지능시스템학회 2004 INTERNATIONAL JOURNAL of FUZZY LOGIC and INTELLIGE Vol.4 No.3

For Web System composed of a variety of hardware, software and network system, there is a wide difference in price, function and capacity. In addition, it is important to select the most suitable system when web system is constructed as the claim of high-quality web service from user has increased. Data of bench-marking is usually employed when the system is selected. Evaluation with the result of bench-marking, however, is not easy at web situation composed of a variety of systems. In this paper, first integrated bench-marking of hardware, software and network system metric were determined, and the plan to effectively compare and evaluate the result of bench-marking by using fuzzy set were offered.

Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model

Cho, Jung Sun,Jeong, Myung Ho,Sim, Doo Sun,Hong, Young Joon,Lim, Kyung Seob,Kim, Jung Ha,Kim, Hyoung Doo,Baek, Ju Yeal,Yoon, Hee Jeoung,Her, Sung-Ho,Jin, Seung Won,Kim, Ju Han,Ahn, Youngkeun,Cho, Jeon The Korean Academy of Medical Sciences 2010 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.25 No.5

<P>The aim of this study was to examine the anti-proliferative and anti-inflammatory effects of ezetimibe/simvastatin (E/S) after drug-eluting stent (DES) implantation in a porcine coronary restenosis model. Pigs were randomized into two groups in which the coronary arteries (23 pigs) had DES. Stents were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries. Fifteen pigs were taken 10/20 mg of E/S and eight pigs were not taken E/S. Histopathologic analysis was assessed at 28 days after stenting. In neointima, most inflammatory cells were lymphohistiocytes. Lymphohistiocyte count was not different between two groups (337±227 vs. 443±366 cells, <I>P</I>=0.292), but neointima area was significantly smaller (1.00±0.49 mm<SUP>2</SUP> vs. 1.69±0.98 mm<SUP>2</SUP>, <I>P</I>=0.021) and percent area stenosis was significantly lower (23.3±10% vs. 39±19%, <I>P</I>=0.007) in E/S group compared with control group. There were no significant differences in fibrin score (1.99±0.79 vs. 1.81±0.88, <I>P</I>=0.49), endothelial score (1.75±0.66 vs. 1.80±0.59, <I>P</I>=0.79), and the percent of endothelium covered lumen (43±21% vs. 45±21%, <I>P</I>=0.84) between E/S group and control group. Combined therapy with ezetimibe and simvastatin inhibits neointimal hyperplasia, but does not inhibit inflammatory infiltration and arterial healing after DES implantation in a porcine coronary restenosis model.</P>

Cavernous Hemangioma of the Gallbladder: a Case Report

Park, Jae Hwi,Lee, Jeong Sub,Choi, Guk Myung,Kim, Bong Soo,Kim, Seung Hyoung,Kim, JeongJae,Kim, Doo Ri,Hyun, Chang Lim,Her, Kyu Hee Korean Society of Magnetic Resonance in Medicine 2019 Investigative Magnetic Resonance Imaging Vol.23 No.3

Cavernous hemangioma of the gallbladder is an extremely rare benign tumor. The tumor has only a few cases being reported in literature. However, to the best of our knowledge, no reports focusing on the MRI findings of cavernous hemangioma of the gallbladder have been published. This study reports a case of gallbladder hemangioma with pathologic and radiologic reviews, including MRI findings.

Contrast Volume/Raw eGFR Ratio for Predicting Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention for Myocardial Infarction

Park, Hoon Suk,Kim, Chan Joon,Yi, Jeong-Eun,Hwang, Byung-Hee,Kim, Tae-Hoon,Koh, Yoon Seok,Park, Hun-Jun,Her, Sung-Ho,Jang, Sung Won,Park, Chul-Soo,Lee, Jong Min,Kim, Hee Yeol,Jeon, Doo Soo,Kim, Pum-Jo S. Karger AG 2015 Cardiorenal medicine Vol.5 No.1

<P>Abstract</P><P><B><I>Background:</I></B> Considering that contrast medium is excreted through the whole kidney in a similar manner to drug excretion, the use of raw estimated glomerular filtration rate (eGFR) rather than body surface area (BSA)-normalized eGFR is thought to be more appropriate for evaluating the risk of contrast-induced acute kidney injury (CI-AKI). <B><I>Methods:</I></B> This study included 2,189 myocardial infarction patients treated with percutaneous coronary intervention. Logistic regression analysis was performed to identify the independent risk factors. We used receiver-operating characteristic (ROC) curves to compare the ratios of contrast volume (CV) to eGFR with and without BSA normalization in predicting CI-AKI. <B><I>Results:</I></B> The area under the curve (AUC) of the ROC curve for the model including all the significant variables such as diabetes mellitus, left ventricular ejection fraction, preprocedural glucose, and the CV/raw modification of diet in renal disease (MDRD) eGFR ratio was 0.768 [95% confidence interval (CI), 0.720-0.816; p < 0.001]. When the CV/raw MDRD eGFR ratio was used as a single risk value, the AUC of the ROC curve was 0.650 (95% CI, 0.590-0.711; p < 0.001). When the CV/MDRD eGFR ratio with BSA normalization ratio was used, the AUC of the ROC curve further decreased to 0.635 (95% CI, 0.574-0.696; p < 0.001). The difference between the two AUCs was significant (p = 0.002). <B><I>Conclusions:</I></B> Raw eGFR is a better predictor for CI-AKI than BSA-normalized eGFR.</P><P>© 2015 S. Karger AG, Basel</P>

Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention

Choo, Eun Ho,Chang, Kiyuk,Ahn, Youngkeun,Jeon, Doo Soo,Lee, Jong Min,Kim, Dong Bin,Her, Sung-Ho,Park, Chul Soo,Kim, Hee Yeol,Yoo, Ki-Dong,Jeong, Myung Ho,Seung, Ki-Bae BMJ Publishing Group Ltd 2014 Heart Vol.100 No.6

<P><B>Objective</B></P><P>β-blockers are the standard treatment for myocardial infarction (MI) based on evidence from the pre-thrombolytic era. The aim of this study was to examine the effect of β-blocker treatment in patients with acute MI and preserved systolic function in the era of percutaneous coronary intervention (PCI).</P><P><B>Methods</B></P><P>We analysed a multicentre registry and identified 3019 patients who presented with acute MI between 2004 and 2009. Patients were treated with PCI, had left ventricular EFs ≥50% according to echocardiograms that were performed during the index PCI, and were alive at the time of discharge. The association between β-blocker use after discharge and mortality (all-cause death and cardiac death) within 3 years was examined.</P><P><B>Results</B></P><P>Patients who were not treated with β-blockers (n=595) showed higher rates of all-cause death and cardiac death compared to patients treated with β-blockers (10.8% vs 5.7%, p<0.001, 7.6% vs 2.6%, p<0001). The multivariate Cox proportional hazards model showed that β-blocker treatment was associated with a significant reduction in all-cause death (adjusted HR 0.633, 95% CI 0.464 to 0.863; p=0.004) and cardiac death (adjusted HR 0.47, 95% CI 0.32 to 0.70; p<0.001). Comparable results were obtained after propensity score matching.</P><P><B>Conclusions</B></P><P>β-blocker treatment was associated with reduced long term mortality in patients with acute MI and preserved systolic function who received PCI.</P>

Assessment of Embryotoxicity of 2-Bromopropane in ICR Mice

Jong-Choon Kim,Dong-Ho Shin,Sung-Ho Kim,Ki-Seok Oh,Hyeon-Yeong Kim,Jeong-Doo Her,Cheng-Zhe Jiang,Moon-Koo Chung 한국독성학회 2003 Toxicological Research Vol.19 No.3

2-Bromopropane (2-BP), a halogenated propane analogue, is a substitute for chlorofluorocarbones (CFCs) which have a great potential to destroy the ozone layer and to warm the earth's environment. The present study was undertaken to evaluate the potential adverse effects of 2-BP on pregnant dams and embryo-fetal development after maternal exposure during the gestational days (GD) 6 through 17 in ICR mice. The test chemical was administered subcutaneously to pregnant mice at dose levels of 0, 313, 625 or 1,250 mg/kg/day. All dams were subjected to caesarean section on GD 18 and their fetuses were examined for external, visceral and skeletal abnormalities. In the 1,250 mg/kg group, maternal toxicity included an increase in the incidence of abnormal clinical signs and a decrease in the maternal body weight, body weight gain, and corrected body weight. Developmental toxicity included a decrease in the fetal body weight, a reduction in the placental weight, an increase in the fetal skeletal variation and ossification delay. There were no adverse effects on either pregnant dams or embryo-fetal development in the 313 and 625 mg/kg groups. These results suggest that a 12-day subcutaneous dose of 2-BP is embryotoxic at a maternally toxic dose (i.e., 1,250 mg/kg/day) in ICR mice. In the present experimental condition, the noobserved-adverse-effect level of 2-BP is considered to be 625 mg/kg/day for dams and embryofetuses, respectively.

Dose-response Effects of Bleomycin on Inflammation and Pulmonary Fibrosis in Mice

Soo Nam Kim,Jinsoo Lee,Hyo-Seon Yang,Jae-Woo Cho,Soonjin Kwon,Young-Beom Kim,Jeong-Doo Her,Kyu-Hyuk Cho,Chang-Woo Song,Kyuhong Lee 한국독성학회 2010 Toxicological Research Vol.26 No.3

Many studies have reported that bleomycin, anti-cancer drug, induces pulmonary fibrosis as a side effect. However, few investigations have focused on the dose-response effects of bleomycin on pulmonary fibrosis. Therefore, in the present study, we investigated the effects of different doses of bleomycin in male mice. ICR mice were given 3 consecutive doses of bleomycin: 1, 2, or 4 ㎎/㎏ in bleomycin-treated (BT) groups and saline only in vehicle control (VC) groups. The animals were sacrificed at 7 and 24 days postinstillation. The severity of pulmonary fibrosis was evaluated according to inflammatory cell count and lactate dehydrogenase (LDH) activity in the broncho alveolar lavage fluid (BALF), and lung tissues were histologically evaluated after hematoxylin and eosin (H&E), and Masson’s trichrome staining. BT groups exhibited changed cellular profiles in BAL fluid compared to the VC group, which had an increased number of total cells, neutrophils, and lymphocytes and a modest increase in the number of macrophages at 7 days post-bleomycin instillation. Moreover, BT groups showed a dose-dependent increase in LDH levels and inflammatory cell counts. However, at 24 days after treatment, collagen deposition, interstitial thickening, and granulomatous lesions were observed in the alveolar spaces in addition to a decrease in inflammatory cells. These results indicate that pulmonary fibrosis induced by 4 ㎎/㎏ bleomycin was more severe than that induced by 1 or 2 ㎎/㎏. These data will be utilized in experimental animal models and as basic data to evaluate therapeutic candidates through non-invasive monitoring using the pulmonary fibrosis mouse model established in this study.

Dose-response Effects of Bleomycin on Inflammation and Pulmonary Fibrosis in Mice

Kim, Soo-Nam,Lee, Jin-Soo,Yang, Hyo-Seon,Cho, Jae-Woo,Kwon, Soon-Jin,Kim, Young-Beom,Her, Jeong-Doo,Cho, Kyu-Hyuk,Song, Chang-Woo,Lee, Kyu-Hong Korean Society of ToxicologyKorea Environmental Mu 2010 Toxicological Research Vol.27 No.3

Many studies have reported that bleomycin, anti-cancer drug, induces pulmonary fibrosis as a side effect. However, few investigations have focused on the dose-response effects of bleomycin on pulmonary fibrosis. Therefore, in the present study, we investigated the effects of different doses of bleomycin in male mice. ICR mice were given 3 consecutive doses of bleomycin: 1, 2, or 4 mg/kg in bleomycin-treated (BT) groups and saline only in vehicle control (VC) groups. The animals were sacrificed at 7 and 24 days postinstillation. The severity of pulmonary fibrosis was evaluated according to inflammatory cell count and lactate dehydrogenase (LDH) activity in the broncho alveolar lavage fluid (BALF), and lung tissues were histologically evaluated after hematoxylin and eosin (H&E), and Masson's trichrome staining. BT groups exhibited changed cellular profiles in BAL fluid compared to the VC group, which had an increased number of total cells, neutrophils, and lymphocytes and a modest increase in the number of macrophages at 7 days post-bleomycin instillation. Moreover, BT groups showed a dose-dependent increase in LDH levels and inflammatory cell counts. However, at 24 days after treatment, collagen deposition, interstitial thickening, and granulomatous lesions were observed in the alveolar spaces in addition to a decrease in inflammatory cells. These results indicate that pulmonary fibrosis induced by 4 mg/kg bleomycin was more severe than that induced by 1 or 2 mg/kg. These data will be utilized in experimental animal models and as basic data to evaluate therapeutic candidates through non-invasive monitoring using the pulmonary fibrosis mouse model established in this study.

Assessment of Embryotoxicity of 2-Bromopropane in ICR Mice

Kim, Jong-Choon,Shin, Dong-Ho,Kim, Sung-Ho,Oh, Ki-Seok,Kim, Hyeon-Yeong,Her, Jeong-Doo,Jiang, Cheng-Zhe,Chung, Moon-Koo Korean Society of ToxicologyKorea Environmental Mu 2003 Toxicological Research Vol.19 No.3

2-Bromopropane (2-BP), a halogenated propane analogue, is a substitute for chlorofluorocarbones (CFCs) which have a great potential to destroy the ozone layer and to warm the earth's environment. The present study was undertaken to evaluate the potential adverse effects of 2-BP on pregnant dams and embryo-fetal development after maternal exposure during the gestational days (GD) 6 through 17 in ICR mice. The test chemical was administered subcutaneously to pregnant mice at dose levels of 0, 313, 625 or 1,250 mg/kg/day. All dams were subjected to caesarean section on GD 18 and their fetuses were examined for external, visceral and skeletal abnormalities. In the 1,250 mg/kg group, maternal toxicity included an increase in the incidence of abnormal clinical signs and a decrease in the maternal body weight, body weight gain, and corrected body weight. Developmental toxicity included a decrease in the fetal body weight, a reduction in the placental weight, an increase in the fetal skeletal variation and ossification delay. There were no adverse effects on either pregnant dams or embryo-fetal development in the 313 and 625 mg/kg groups. These results suggest that a 12-day subcutaneous dose of 2-BP is embryotoxic at a maternally toxic dose (i.e., 1,250 mg/kg/day) in ICR mice. In the present experimental condition, the no-observed-adverse-effect level of 2-BP is considered to be 625 mg/kg/day for dams and embryo-fetuses, respectively.